Poster Presentations Session I
Poster Presentations Session I Saturday, 16 September 2017
POSTERS SET-UP: 8:15 - 8:30
POSTERS DISPLAY HOURS: 8:30 - 20:00
POSTER AUTHOR DISCUSSION: 18:30 - 19:30
POSTERS DISMANTLE: 20:00


Poster display locations are shown below the poster codes
CANCER - Clinical Outcomes Studies
PCN1
D15
ADDING RAMUCIRUMAB TO SECOND-LINE IRINOTECAN, 5-FLUOROURACIL AND FOLINIC ACID (FOLFIRI) TREATMENT FOR METASTATIC COLORECTAL CARCINOMA (MCRC): RESOURCE UTILIZATION DATA FROM RAISE, A GLOBAL, RANDOMIZED, DOUBLE-BLIND, MULTICENTER PHASE 3 STUDY
Brück P1, Kisro J2, Cohn AL3, Yoshino T4, Van Cutsem E5, Hegewisch-Becker S6, Kullmann F7, Liepa AM8, Yang L9, Nasroulah F9, Tabernero J10
1Lilly Deutschland GmbH, Bad Homburg, Germany, 2Onkologisches Zentrum Lübeck e.V, Lübeck, Germany, 3Rocky Mountain Cancer Center/US Oncology, Denver, CO, USA, 4National Cancer Center Hospital East, Chiba, Japan, 5University Hospitals Gasthuisberg, Leuven, Belgium, 6Hematological/Oncological Practice, Hamburg, Germany, 7Klinikum Weiden, Weiden, Germany, 8Eli Lilly and Company, Indianapolis, IN, USA, 9Eli Lilly and Company, Bridgewater, NJ, USA, 10Vall d'Hebron University Hospital, Barcelona, Spain

PCN2
D16
EFFICACY AND COST-EFFECTIVENESS OF SECOND-LINE CHEMOTHERAPY IN ELDERLY PATIENTS WITH ADVANCED GASTRIC CANCER
Zhou K
Sichuan University, Chengdu, China

PCN3
D17
INTRACORPOREAL VERSUS EXTRACORPOREAL ANASTOMOSIS IN LAPAROSCOPIC RIGHT HEMICOLECTOMY: A SYSTEMATIC REVIEW AND META-ANALYSIS
Oliveira D1, Luque A2, Oliveira FM1, Junqueira Junior SM1
1Johnson & Johnson Medical Brazil, São Paulo, Brazil, 2Johnson&Johnson Medical Brazil, Sao Paulo, Brazil

PCN4
D18
ANÁLISE DA QUALIDADE DA EVIDÊNCIA CIENTÍFICA ENTRE XELOX E FOLFOX NO TRATAMENTO DO CÂNCER COLORRETAL
Boscato SC1, Godoy MR2, Heineck I1
1Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2Instituto de Avaliação de Tecnologia em Saúde - IATS, Porto Alegre, Brazil

PCN5
WITHDRAWN

PCN6
WITHDRAWN

PCN7
E1
CETUXIMAB IN THE TREATMENT OF MCRC LIVER LIMITED DISEASE: A SYSTEMATIC REVIEW
Correa Jd1, Amaral LM2, Biglia LV3, Souza PV3, Blum RR3
1SENSE Company, Rio de Janeiro, Brazil, 2Sense Company, Rio de Janeiro, Brazil, 3Merck, São Paulo, Brazil

PCN8
E2
EVALUATING ACCESS TO TREATMENT: A COMPARISON OF THE EXPECTED NUMBER OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) TO THOSE EFFECTIVELY TREATED IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM
Kim HS, Fahham L
SENSE Company, São Paulo, Brazil

PCN9
E3
MULTIPLE MYELOMA: EPIDEMIOLOGY AND BURDEN OF DISEASE ANALYSIS IN LATIN AMERICA
Pineli M1, Pinho W1, Amigo C2, Alvarado CA3, Figueroa R4, Bucheli E5
1Takeda Pharmaceuticals Brazil, São Paulo, Brazil, 2Takeda Pharma S.A., Buenos Aires, Argentina, 3Takeda Colombia, Bogotá, Colombia, 4Takeda México S.A de C.V, Naucalpan, Mexico, 5Takeda Ecuador Cía. Ltda., Quito, Ecuador

PCN10
E4
PATIENT AND TUMOR PROFILES IN THE BRAZILIAN PRIVATE SETTING: DATA FROM THE AUDITRON CLAIMS DATABASE
Julian GS, Saad R, de Oliveira RW, Moreira Ed
Evidências - Kantar Health, São Paulo, Brazil

PCN11
E5
ANALYZING OVARIAN CANCER RECURRENCE AFTER TUMOR RESECTION IN OTHER SITES THROUGH THE BRAZILIAN PUBLIC HEALTHCARE CLAIM DATABASES (DATASUS)
Rosim RP, Campos DF, Duva AS, Hirth WA, Ballalai Ferraz AF
QuintilesIMS, São Paulo, Brazil

PCN12
E6
EFECTO DEL 1B8 EN EL TRATAMIENTO DE PACIENTES CON LINFOMA NO HODGKIN CD20+
Saumell Nápoles Y1, Hernández C1, Cepero K2, Fernández JD3, Marín D4, de la Torre AV5, Rodríguez G6, Älvarez N7, Lorenzo-Luaces P8
1Institute of Molecular Immunology, Havana, Cuba, 2Institute of Molecular Immunology, Cienfuegos, Cuba, 3Gustavo aldereguía´s Hospital, Cienfuegos, Cuba, 4Abel santamaría´s Hospital, Pinar del Río, Cuba, 5Celestino Hernández´Hospital, Villa Clara, Cuba, 6Camilo Cienfuegos´Hospital, Sancti Spíritus, Cuba, 7Faustino Pérez´ Hospital, Matanzas, Cuba, 8Center of Molecular Immunology, Habana, Cuba

CANCER - Cost Studies
PCN13
E7
ANÁLISE DE IMPACTO ORÇAMENTÁRIO DO AXITINIBE NA SEGUNDA LINHA DE TRATAMENTO DO CARCINOMA DE CÉLULAS RENAIS METASTÁTICO SOB A PERSPECTIVA DO SISTEMA PRIVADO DE SAÚDE BRASILEIRO
Alexandre RF, Squiassi HB, Santana CF
Pfizer, São Paulo, Brazil

PCN14
E8
ANÁLISE DE IMPACTO ORÇAMENTÁRIO DO CRIZOTINIBE NO TRATAMENTO DO CÂNCER DE PULMÃO NÃO PEQUENAS CÉLULAS AVANÇADO ALK-POSITIVO SOB A PERSPECTIVA DO SISTEMA PRIVADO DE SAÚDE BRASILEIRO
Alexandre RF, Squiassi HB, Santana CF
Pfizer, São Paulo, Brazil

PCN15
E9
ANTECIPAÇÃO AO ROL DE PROCEDIMENTOS DA AGÊNCIA NACIONAL DE SAÚDE SUPLEMENTAR: IMPACTO ORÇAMENTÁRIO DA INCORPORAÇÃO DE UM NOVO INIBIDOR DE TIROSINA-QUINASE.
Albuquerque IM, Sartori DP, Vieira JB, Romero JF, Neto Vd, França AP, Nunes FM, Viana A, Rodrigues P, Gontei M, Junior AN, Rodrigues EX
UNIMED Fortaleza, Fortaleza, Brazil

PCN16
E10
GASTO FARMACÉUTICO AMBULATORIO Y HOSPITALARIO EN PACIENTES CON CÁNCER DE MAMA EN LA COMUNIDAD DE VALENCIA. ANÁLISIS DE LO GRUPOS DE RIESGO CLÍNICO 2014-2015.
Albanes Beltran JP1, Vivas Consuelo D2, Romero M3, Caballer V4, Alvis-Guzmán N5, De la Hoz Restrepo F1
1Universidad Nacional de Colombia, Bogotá, D.C., Colombia, 2Universidad Politécnica de Valencia, Valencia, Spain, 3Fundación Salutia, Bogotá D.C., Colombia, 4Universitat Politècnica de València, Valencia, Spain, 5Universidad de Cartagena, Centro de Investigación y Docencia, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia

PCN17
E11
ECONOMIC EVALUATION OF THE CHANGE FROM AN OPPORTUNISTIC CERVICAL SCREENING PROGRAM TO AN ORGANIZED SCREENING IN CATALONIA, SPAIN
Diaz M, Moriña D, Ibáñez R, Bruni L, de Sanjose S
Catalan Institute of Oncology-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain

PCN18
E12
QUIMIOTERÁPICOS ORAIS NO TRATAMENTO DE SEGUNDA LINHA DO CARCINOMA DE CÉLULAS RENAIS: COMPARAÇÃO DE CUSTOS E PERFIL DE REAÇÕES ADVERSAS.
Albuquerque IM, Vieira JB, Sartori DP, Romero JF, Neto Vd, Nunes FM, Rodrigues P, Viana A, Gontei M, Junior AN, Rodrigues EX
UNIMED Fortaleza, Fortaleza, Brazil

PCN19
E13
XELOX VERSUS FOLFOX NO TRATAMENTO DO CÂNCER COLORRETAL: REVISÃO DE ESTUDOS FARMACOECONÔMICOS
Boscato SC1, Godoy MR2, Heineck I1
1Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2Instituto de Avaliação de Tecnologia em Saúde - IATS, Porto Alegre, Brazil

PCN20
E14
IMPACTO DEL CAMBIO DE PRESENTACIÓN DEL TRASTUZUMAB PARA LA SEGURIDAD SOCIAL DE COSTA RICA, ESTUDIO DE MINIMIZACIÓN DE COSTOS
Castro Cordero JA, Marin Piva H, Ching Fung SM
Caja Costarricense de Seguro Social, San Jose, Costa Rica

PCN21
E15
THE BURDEN OF UROTHELIAL CARCINOMA FOR THE BRAZILIAN PUBLIC HEALTH SYSTEM: A NATIONAL RETROSPECTIVE ANALYSIS FROM 2013 TO 2016
Chabrol Haas L, Peixoto RB, Coutinho MB, Serra FB
MSD Brasil, São Paulo, Brazil

PCN22
E16
CUSTOS DIRETOS NO TRATAMENTO DE CÂNCER DE MAMA: OLHAR ESTRATÉGICO DE UMA OPERADORA DE PLANOS DE SAÚDE DO BRASIL.
Albuquerque IM, Sartori DP, Vieira JB, Romero JF, Neto Vd, Nunes FM, França AP, Viana A, Rodrigues P, Gontei M, Junior AN, Rodrigues EX
UNIMED Fortaleza, Fortaleza, Brazil

PCN23
E17
RESOURCE UTILIZATION AND TREATMENT OF PATIENT WITH HEPATOCELULLAR CARCINOMA – A MICROCOSTING ANALYSIS
Turri JA1, Decimoni TC2, Ferreira LA3, Tomitao M4, Campolina AG4
1Sao Paulo Medical School - Sao Paulo University, Sao Paulo, Brazil, 2Sao Paulo Medical School, Sao Paulo, SK, Brazil, 3University of Sao Paulo, Sao Paulo, Brazil, 4Cancer Institute of the State of Sao Paulo, Sao Paulo, Brazil

PCN24
E18
ECONOMIC ANALYSIS OF HEPATO CELLULAR CARCINOMA TREATMENT BY SEVERITY OF DISEASE
Turri JA1, Campolina AG2, Decimoni TC3, Tomitao M2, Ferreira LA4
1Sao Paulo Medical School - Sao Paulo University, Sao Paulo, Brazil, 2Cancer Institute of the State of Sao Paulo, Sao Paulo, Brazil, 3Sao Paulo Medical School, Sao Paulo, SK, Brazil, 4University of Sao Paulo, Sao Paulo, Brazil

PCN25
F1
OBINUTUZUMAB VS. IBRUTINIB IN THE TREATMENT OF TREATMENT-NAÏVE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA —A COST-COMPARISON STUDY IN COLOMBIA
Vecino-Ortiz A1, Díaz-Sotelo OD2, Rodríguez M3, Diaz-Toro YR4, Moreno-Silva NA4
1Universidad de los Andes, Bogota, Colombia, 2Random Foundation, Bogota, Colombia, 3Fundación Santa Fe de Bogotá, Bogota, Colombia, 4Productos Roche S.A. Colombia, Bogotá, Colombia

PCN26
F2
CETUXIMAB IN THE FIRST-LINE TREATMENT OF RAS WILD-TYPE METASTATIC COLORECTAL CANCER WITH LIVER-LIMITED DISEASE
Souza PV1, Zanini FE1, Biglia LV1, Kim HS2, Fahham L2
1Merck, São Paulo, Brazil, 2SENSE Company, São Paulo, Brazil

PCN27
F3
COST PER RESPONSE ANALYSIS OF NIVOLUMAB VERSUS EVEROLIMUS IN THE TREATMENT OF PATIENTS PREVIOUSLY TREATED WITH ADVANCED RENAL CELL CARCINOMA – BRAZIL PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
Brust L1, Bernardino G2, Aratangy G2, Tanaka S2, Paladini L3, Borges L3, Clark OA4
1Centro Universitário Univates, Rio Grande do Sul, Brazil, 2Bristol-Myers Squibb, São Paulo, Brazil, 3Evidencias - Kantar Health, Campinas, Brazil, 4Evidencias - Kantar Health, Campinas, NJ, Brazil

PCN28
F4
WITHDRAWN

PCN29
F5
COST CONSEQUENCE ANALYSIS OF IMMUNE-ENHANCING NUTRITIONAL FORMULA IN PATIENTS WITH DIGESTIVE CANCER SURGERY
Danel A1, Viana SD2, Dias A2, Lopez SN2, Tauil DA2, Meale MM2
1Nestle Health Science, Vevey, Switzerland, 2Nestle Health Science, Sao Paulo, Brazil

PCN30
WITHDRAWN

PCN31
F6
INHIBITORS OF TIROSIN KINASA IN CHRONIC MIELOID LEUKEMIA: COST-EFFECTIVENESS ANALYSIS.
Campos I1, Cordova P2, Fernandez P2, Lopez M2, Morales F2, Villa L2
1Universidad de Concepción, Concepción, Chile, 2Facultad de Farmacia, Universidad de Concepción, Concepción, Chile

PCN32
F7
ACCUMULATED TREATMENT COST OF NEW THERAPIES IN MULTIPLE MYELOMA: COMPARING THE COMBINATION OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE WITH CARFILZOMIB AND DEXAMETHASONE FOR WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY IN BRAZIL
Del Rey C, Asano E
Janssen, Sao Paulo, Brazil

PCN33
F8
TREATMENT SEQUENCING FOR PATIENTS WITH MULTIPLE MYELOMA WITH AT LEAST ONE PRIOR LINE: COMPARING PROGRESSION-FREE SURVIVAL AND COSTS UNDER A PRIVATE PAYER PERSPECTIVE
Asano E1, Maiolino A2, Martins E1
1Janssen, Sao Paulo, Brazil, 2UFRJ, Rio de Janeiro, Brazil

PCN34
F9
COST AND EFFECTIVENESS OF THE USE OF SORAFENIB IN DIFFERENTIATED THYROID CANCER
Carrasquilla-Sotomayor M1, Alvis-Zakzuk NJ2, Gomez de la Rosa F2, Alvis Zakzuk J1, Marrugo Figueroa RD3, Miranda Machado P1, Alvis Guzman N4, Herran Diazgranado SE3
1ALZAK Group, CARTAGENA, Colombia, 2ALZAK Foundation, Cartagena, Colombia, 3Bayer, Bogotá, Colombia, 4ALZAK Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia

PCN35
F10
ESTUDIO DE COSTO-EFECTIVIDAD E IMPACTO PRESUPUESTAL DE DENOSUMAB VS. ÁCIDO ZOLEDRÓNICO PARA EL MANEJO DE METÁSTASIS ÓSEAS EN PACIENTES CON CÁNCER DE PRÓSTATA EN COLOMBIA
Pérez M1, Garcia Perlaza J1, Fletscher PM1, Vargas-Valencia J2
1AMGEN, Bogotá, Colombia, 2Econopharma Consulting, Mexico, Mexico

PCN36
F11
COST PER MEDIAN OVERALL SURVIVAL ASSOCIATED WITH ABIRATERONE ACETATE AND ENZALUTAMIDE FOR TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN COLOMBIA
Aguirre A1, Guerrero E2
1Janssen Cilag SA, Bogota, Colombia, 2Janssen Colombia, Bogota, Colombia

PCN37
F12
COSTO UTILIDAD DE LOS BLOQUEADORES HER2 CONTRA EL CÁNCER DE MAMA METASTÁSICO EN MUJERES PERUANAS
Gutierrez-Aguado A1, Escobedo-Palza S2
1UNMSM, Lima, Peru, 2SPEAS, Lima, Peru

CANCER - Patient-Reported Outcomes & Patient Preference Studies
PCN38
F13
ONCOLOGIC PAIN ATTITUDES, INTENSITY AND TREATMENT IN BRAZIL
Holtz L1, Julian GS2, Cecilio L1, de Oliveira RW2, Moreira Ed2
1Oncoguia, São Paulo, Brazil, 2Evidências - Kantar Health, São Paulo, Brazil

PCN39
F14
WITHDRAWN

CANCER - Health Care Use & Policy Studies
PCN40
F15
PINK OCTOBER IN THE SOCIAL MEDIA: ARE WE STILL (MIS)GUIDING THE PUBLIC?
Bueno CC, Almeida PR, Clark LG
Evidencias - Kantar Health, Campinas, Brazil

PCN41
F16
SUPPORTING INDIVIDUAL REFLECTION AND PATIENT-CLINICIAN SHARED DECISION-MAKING ON GEP-NET MANAGEMENT OPTIONS USING REFLECTIVE MULTI-CRITERIA DECISION ANALYSIS
Wagner M1, Samaha D2, O'Neil B3, Khoury H3, Bennetts L3, Lavoie L3, Badgley D3, Gabriel S4, Berthon A4, Dinet J4, Dolan J5, Kulke MH6, Goetghebeur MM7
1Analytica LASER, Montreal, QC, Canada, 2LASER Analytica, London, UK, 3LASER Analytica, Montreal, QC, Canada, 4Ipsen Pharma SAS, Boulogne-Billancourt, France, 5University of Rochester, Rochester, NY, USA, 6Dana-Farber Cancer Institute, Boston, MA, USA, 7Analytica LASER and School of Public Health, University of Montreal, Montreal, QC, Canada

PCN42
F17
BREAST CANCER DIAGNOSIS PROCESS: AN INTEGRATIVE EVALUATION OF FIVE COMPONENTS.
Pulido DC1, Alvis LF1, Gonzalez J2, Sanchez P1, Acuña L1, Bryón A3
1Fondo Colombiano de Enfermedades de Alto Costo, Bogotá, Colombia, 2Oncólogos de Occidente, Pereira, Colombia, 3HEORT- Health Economics & Outcomes Research Team, Bogota, Colombia

PCN43
F18
MULTIPLE MYELOMA PATIENTS’ PROFILE AND REGIMENS TRANSITIONS IN THE BRAZILIAN PRIVATE HEALTH SECTOR
Lin HM1, Luptakova K1, Tanaka PY2, Andrade F2, Saad R3, Clark OA4
1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 2Takeda Farmacêutica Brasil, São Paulo, Brazil, 3Evidencias - Kantar Health, Campinas, Brazil, 4Evidencias - Kantar Health, Campinas, NJ, Brazil

PCN44
G1
USE OF BRENTUXIMAB VEDOTIN TO TREAT HODGKIN LYMPHOMA IN A PRIVATE SECTOR SETTING IN BRAZIL
Andrade F1, Barreto T1, Zagadailov E2, Gautam A2, Clark OA3, Saad R4, Seal B2, Dalal M2, Baiocchi O5
1Takeda Farmacêutica Brasil, São Paulo, Brazil, 2Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 3Evidencias - Kantar Health, Campinas, NJ, Brazil, 4Evidencias - Kantar Health, Campinas, Brazil, 5Universidade Federal de São Paulo, São Paulo, Brazil

PCN45
G2
ANALYSIS OF METASTATIC BREAST CANCER POLICIES TO ADVANCE ACCESS TO TREATMENT IN LATIN AMERICA: RESEARCH METHODOLOGY AND APPROACHES USED TO SURVEY THE CURRENT POLICY ENVIRONMENT
Dharssi S, Thrift Perry M
Pfizer, Inc, New York, NY, USA

PCN46
G3
ANTINEOPLÁSICOS DE MAIOR IMPACTO FINANCEIRO NO INSTITUTO NACIONAL DE CANCER DO BRASIL
Moraes EL1, Osorio-de-Castro CG2, Caetano R3
1National Cancer Institute, Rio de Janeiro, Brazil, 2Sergio Arouca National School of Public Health,Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, 3Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio de Janeiro, Brazil

PCN47
G4
COMPRAS DE MEDICAMENTOS SEM LICITAÇÃO NO INSTITUTO NACIONAL DE CÂNCER DO BRASIL
Moraes EL1, Osorio-de-Castro CG2, Caetano R3
1National Cancer Institute, Rio de Janeiro, Brazil, 2Sergio Arouca National School of Public Health,Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, 3Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio de Janeiro, Brazil

PCN48
G5
HIGH-COST ONCOLOGY DRUGS IN BRAZIL AND MEXICO: ACCESS DIFFERENCES BETWEEN THE PUBLIC AND PRIVATE SETTINGS
Giao Antunes NT1, Ribeiro A1, Duval A2, Moore R3
1Decision Resources Group, Burlington, MA, USA, 2Decision Resources Group, London, UK, 3Decision Resources Group, Nashville, TN, USA

PCN49
G6
REAL WORLD DATA ON MULTIPLE MYELOMA TREATMENT PATTERNS: FIRST AND SECOND-LINE TREATMENT IN THE BRAZILIAN PUBLIC HEALTH SYSTEM
Lemmer T1, Martins RE1, Kashiura D1, Saad R2
1Evidências - Kantar Health, São Paulo, Brazil, 2Evidencias - Kantar Health, Campinas, Brazil

PCN50
G7
ANÁLISE SITUACIONAL DO TRATAMENTO CIRÚRGICO DO CÂNCER COLORRETAL NO BRASIL
Oliveira D1, Oliveira FM1, Junqueira Junior SM1, Luque A2
1Johnson & Johnson Medical Brazil, São Paulo, Brazil, 2Johnson&Johnson Medical Brazil, Sao Paulo, Brazil

PCN51
G8
EVALUATION OF HEALTH CARE REFORM IMPACT ON CANCER PATIENTS` ACCESS TO MEDICINE: A PILOT-CENTER EXPERIENCE IN ISLAMIC REPUBLIC OF IRAN
Mansoori M1, Zaboli P2, Saeedi M1, Janbabai G1, Nikfar S2, Rohani E3, Zartab S2
1Mazandaran University of Medical Sciences, Sari, Iran (Islamic Republic of), 2Tehran University of Medical Sciences, Faculty of Pharmacy, Tehran, Iran (Islamic Republic of), 3Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of)

PCN52
G9
HEMATOPOIETIC CELL TRANSPLANTATION FACILITIES: GEOGRAPHIC ACCESS IN COLOMBIA.
Uribe Parra D1, Soler LA1, Lopes G2, Acuña Merchan L1, Bermúdez NC1, Valencia O1, Gonzalez J3, Pulido DC1, Sanchez P1, Gutierrez A1
1Fondo Colombiano de Enfermedades de Alto Costo, Bogotá, Colombia, 2Sylvester Comprehensive Cancer Center at the University of Miami and the Miller School of Medicine, Miami, FL, 33136, Colombia, 3Oncólogos de Occidente, Pereira, Colombia

PCN53
G10
EVALUATION OF HEALTH CARE REFORM IMPACT ON CANCER PATIENTS` TOTAL OUT OF POCKET: A PILOT-CENTER EXPERIENCE IN ISLAMIC REPUBLIC OF IRAN
Sarkhanloo F1, Zaboli P2, Saeedi M1, Janbabai G1, Nikfar S3, Morteza-Semnani K4, Rohani E2, Ayati N2
1Mazandaran University of Medical Sciences, Sari, Iran (Islamic Republic of), 2Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), 3Tehran University of Medical Sciences, Faculty of Pharmacy, Tehran, Iran (Islamic Republic of), 4Mazandaran University of Medical sciences, Sari, Iran (Islamic Republic of)

PCN54
G11
QUIMIOTERAPIA DO CÂNCER NAS ÚLTIMAS SEMANAS DE VIDA: ESTUDO RETROSPECTIVO EM BENEFICIÁRIOS DE UM PLANO DE SAÚDE PRIVADO NO BRASIL
Reis Neto JP, Busch JM, Stefani S
Souza Marques University, Rio de Janeiro, Brazil

PCN55
G12
DISTRIBUIÇÃO DAS PRINCIPAIS NEOPLASIAS MALIGNAS SEGUNDO SEXO E ANO DE DIAGNÓSTICO, REGISTRO HOSPITALAR DE CÂNCER, INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO, 2008-2012
López RV1, Campolina AG2, Lopes EF1, Hoff PM3, Chammas R1
1Cancer Institute of the State of São Paulo, Sao Paulo, Brazil, 2Cancer Institute of the State of Sao Paulo, Sao Paulo, Brazil, 3Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil

PCN56
G13
IMPACTO DO ENCAMINHAMENTO PRECOCE PARA CUIDADOS PALIATIVOS NA UTILIZAÇÃO DE ATENDIMENTOS DE EMERGÊNCIA POR PACIENTES COM CÂNCER AVANÇADO
Rozman LM1, Campolina AG2, López RV3, Chiba T3, De Soárez PC4
1University of Sao Paulo, Sao Paulo, Brazil, 2Cancer Institute of the State of Sao Paulo, Sao Paulo, Brazil, 3Cancer Institute of the State of São Paulo, Sao Paulo, Brazil, 4University of Sao Paulo, Sao Paulo, Brazil

PCN57
G14
INFLUÊNCIA DOS FATORES SOCIOECONÔMICOS NA INCIDÊNCIA DE CÂNCER DE MAMA: REVISÃO SISTEMÁTICA
Massuda EM1, Tortajada Jd2, Oliveira TS2, Costa CK3
1Unicesumar/ICETI, MARINGA, Brazil, 2Unicesumar, MARINGA, Brazil, 3Universidade Estadual de Maringá, Maringá, Brazil

PCN58
G15
BEVACIZUMAB FOR BREAST CANCER: SCIENTIFIC EVIDENCE VERSUS REAL WORLD DATA (RWD) IN BRAZIL
Feijo L, Pegoretti Rosa B, Moraes Z, Goes L, Clark LG
Evidencias - Kantar Health, Campinas, Brazil

PCN59
G16
DENIED ONCOLOGY TREATMENT CLAIMS: HOW MUCH DO THEY COST AND HOW CAN WE PREVENT RESOURCE WASTE?
Goes L, Castro AP, Pegoretti Rosa B, Clark LG
Evidencias - Kantar Health, Campinas, Brazil

PCN60
H1
NEWEST TARGET THERAPY AND IMMUNOTHERAPY FOR THE TREATMENT OF ADVANCED MELANOMA: PATTERNS OF ADOPTION BY THE PRIVATE HEALTH CARE SECTOR IN BRAZIL
Pegoretti Rosa B, Goes L, Moraes Z, Feijo L, Clark LG
Evidencias - Kantar Health, Campinas, Brazil

PCN61
H2
REAL-WORLD TREATMENT PATTERNS IN STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN ARGENTINA
Novick D1, Hong J2, Sheffield KM3, Mills BJ4, Gallino J5
1Eli Lilly and Company, Windlesham, Surrey, UK, 2Gachon University, Seongnam, Korea, Republic of (South), 3Eli Lilly and Company, Indianapolis, IN, USA, 4Elilly and Company, Indianapolis, IN, USA, 5Institute of Medical Specialties SA, Pilar, Argentina

PCN62
H3
REAL WORLD TREATMENT PATTERNS IN METASTATIC AND/OR UNRESECTABLE GASTRIC CANCER PATIENTS. PRELIMINARY RESULTS FROM COLOMBIA
Novick D1, Leonardi Reyes F2, Lee Kay Pen ED3, Siddi S4, Haro JM5, Velasquez JC6
1Eli Lilly and Company, Windlesham, Surrey, UK, 2Eli Lilly, Bogota, Colombia, 3LACAM Eli Lilly and Company, LIMA, Peru, 4Parc SanitariSant Joan de Déu, CIBERSAM, Sant Boi de Llobregat, Spain, 5Parc Sanitari Sant Joan de Déu, CIBERSAM, Sant Boi de Llobregat, Spain, 6Instituto Nacional de Cancerología E.S.E, Bogotá, Colombia

PCN63
H4
REAL WORLD TREATMENT PATTERNS IN METASTATIC AND/OR UNRESECTABLE GASTRIC CANCER IN PATIENTS FROM ARGENTINA
Novick D1, Mendenz G2, Carballido M3, Rizzo M3, O'Connor JM4, Castillo J5, Lee Kay Pen ED6, Siddi S7, Rodante D8, Haro JM9
1Eli Lilly and Company, Windlesham, Surrey, UK, 2Fundación Favaloro para la Docencia e Investigación médica, Buenos Aires, Argentina, 3Hospital de Gastroenterología “Dr. Carlos Bonorino Udaondo, Buenos Aires, Argentina, 4Instituto Alexander Fleming, Buenos Aires, Argentina, 5Hospital Alemán Asociación Civil, Buenos Aires, Argentina, 6LACAM Eli Lilly and Company, LIMA, Peru, 7Parc SanitariSant Joan de Déu, CIBERSAM, Sant Boi de Llobregat, Spain, 8Hospital Neuropsiquiátrico "Dr. Braulio A. Moyano", Buenos Aires, Argentina, 9Parc Sanitari Sant Joan de Déu, CIBERSAM, Sant Boi de Llobregat, Spain

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.